WO1995030435A3 - Compositions and treatment for multiple sclerosis - Google Patents

Compositions and treatment for multiple sclerosis Download PDF

Info

Publication number
WO1995030435A3
WO1995030435A3 PCT/US1995/005605 US9505605W WO9530435A3 WO 1995030435 A3 WO1995030435 A3 WO 1995030435A3 US 9505605 W US9505605 W US 9505605W WO 9530435 A3 WO9530435 A3 WO 9530435A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
peptide
administering
multiple sclerosis
mbp
Prior art date
Application number
PCT/US1995/005605
Other languages
French (fr)
Other versions
WO1995030435A2 (en
Inventor
Di-Hwei Hsu
Dawn Smilek
Jia Dong Shi
Original Assignee
Immulogic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharma Corp filed Critical Immulogic Pharma Corp
Priority to CA002189990A priority Critical patent/CA2189990A1/en
Priority to EP95918988A priority patent/EP0758902A1/en
Priority to AU24705/95A priority patent/AU2470595A/en
Priority to SK1458-96A priority patent/SK145896A3/en
Priority to JP7529103A priority patent/JPH10500109A/en
Publication of WO1995030435A2 publication Critical patent/WO1995030435A2/en
Publication of WO1995030435A3 publication Critical patent/WO1995030435A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention provides compositions and methods for treating multiple sclerosis. Compositions of the invention comprise at least one peptide or modified peptide of myelin basic protein (MBP) which comprises at least one T cell epitope, and IFN-β in an appropriate pharmaceutically acceptable medium for either oral, subcutaneous or intravenous administration. Methods of the inven include treatment of individuals who either have MS or are suspected of being susceptible to MS by administering a therapeutically effective amount of a composition of the invention or by administering in a therapeutic regimen, a composition comprising at least one peptide or modified peptide of MBP which comprises at least one T cell epitope and further administering IFN-β.
PCT/US1995/005605 1994-05-10 1995-05-04 Compositions and treatment for multiple sclerosis WO1995030435A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002189990A CA2189990A1 (en) 1994-05-10 1995-05-04 Compositions and treatment for multiple sclerosis
EP95918988A EP0758902A1 (en) 1994-05-10 1995-05-04 Compositions and treatment for multiple sclerosis
AU24705/95A AU2470595A (en) 1994-05-10 1995-05-04 Compositions and treatment for multiple sclerosis
SK1458-96A SK145896A3 (en) 1994-05-10 1995-05-04 Medicaments containing therapeutically effective quantity of antigen peptid of human mbp and ifn-beta
JP7529103A JPH10500109A (en) 1994-05-10 1995-05-04 Compositions and methods of treatment for multiple sclerosis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24124694A 1994-05-10 1994-05-10
US08/241,246 1994-05-10
US32822494A 1994-10-25 1994-10-25
US08/328,224 1994-10-25

Publications (2)

Publication Number Publication Date
WO1995030435A2 WO1995030435A2 (en) 1995-11-16
WO1995030435A3 true WO1995030435A3 (en) 1995-12-07

Family

ID=26934122

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/005605 WO1995030435A2 (en) 1994-05-10 1995-05-04 Compositions and treatment for multiple sclerosis

Country Status (11)

Country Link
EP (1) EP0758902A1 (en)
JP (1) JPH10500109A (en)
AU (1) AU2470595A (en)
CA (1) CA2189990A1 (en)
CZ (1) CZ329596A3 (en)
HU (1) HUT76099A (en)
IL (1) IL113661A0 (en)
PL (1) PL317197A1 (en)
SI (1) SI9520059A (en)
SK (1) SK145896A3 (en)
WO (1) WO1995030435A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2203629A1 (en) * 1994-10-25 1996-05-02 Dawn Smilek Compositions and treatment for multiple sclerosis
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
AU5671196A (en) * 1996-03-28 1997-10-17 Immulogic Pharmaceutical Corporation Myelin oligodendrocyte glycoprotein peptides and uses thereof
WO1998006861A2 (en) * 1996-08-15 1998-02-19 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
AUPP823999A0 (en) * 1999-01-20 1999-02-11 University Of Queensland, The A treatment
US20020025304A1 (en) * 2000-06-16 2002-02-28 Croze Edward M. Novel interferon for the treatment of multiple sclerosis
DE60134862D1 (en) * 2000-08-21 2008-08-28 Apitope Technology Bristol Ltd Tolerogenic peptides
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
CA2480308C (en) 2002-03-27 2011-10-04 Aegera Therapeutics Inc. Antisense iap nucleobase oligomers and uses thereof
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
BG66517B1 (en) 2008-04-08 2016-02-29 Tigo Gmbh Inhibitor of endogenous human interferon - gamma
BG1430U1 (en) * 2010-06-25 2011-04-29 Иван ИВАНОВ Pharmaceutical formulation
BG67190B1 (en) 2017-03-29 2020-11-16 Tigo Gmbh Anti-gama mutant protein against endogenous human gamma interferon

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021222A1 (en) * 1992-04-09 1993-10-28 Autoimmune, Inc. Suppression of t-cell proliferation using peptide fragments of myelin basic protein
WO1994004121A1 (en) * 1992-08-17 1994-03-03 Autoimmune, Inc. Bystander suppression of retroviral-associated neurological disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021222A1 (en) * 1992-04-09 1993-10-28 Autoimmune, Inc. Suppression of t-cell proliferation using peptide fragments of myelin basic protein
WO1994004121A1 (en) * 1992-08-17 1994-03-03 Autoimmune, Inc. Bystander suppression of retroviral-associated neurological disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE FILE SERVER STN KARLSRUHE; ABREU: "INTERFERON IN EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS (EAE):EFFECTS OF EXOGENOUS INTERFERON ON THE ANTIGEN-ENHANCED ADOPTIVE TRANSFER OF EAE" *
PANITCH ET AL: "CLINICAL TRIALS OF INTERFERONS IN MULTIPLE SCLEROSIS.WHAT HAVE WE LEARNED", JOURNAL OF NEUROIMMUNOLOGY, vol. 46, no. 1+2, pages 155 - 164, XP023694964, DOI: doi:10.1016/0165-5728(93)90245-T *

Also Published As

Publication number Publication date
PL317197A1 (en) 1997-03-17
CA2189990A1 (en) 1995-11-16
SI9520059A (en) 1997-08-31
SK145896A3 (en) 1997-05-07
IL113661A0 (en) 1995-08-31
AU2470595A (en) 1995-11-29
CZ329596A3 (en) 1997-05-14
HU9603116D0 (en) 1997-01-28
HUT76099A (en) 1997-06-30
JPH10500109A (en) 1998-01-06
EP0758902A1 (en) 1997-02-26
WO1995030435A2 (en) 1995-11-16

Similar Documents

Publication Publication Date Title
DE69835823T2 (en) METHOD FOR THE TREATMENT OF PATIENTS SUFFERING FROM MULTIPLE SCLEROSIS WITH CONSENSUS INTERFERON
PT735893E (en) Pan dr-binding peptides for enhancement of the immune response
WO1995030435A3 (en) Compositions and treatment for multiple sclerosis
TW265265B (en)
AU6762794A (en) A coagulation factor viii formulation
MY112405A (en) Method of tumer treatment.
CA2170255A1 (en) Pharmaceutical Composition for Immunoenhancement Therapy
NZ293910A (en) Peptides useful in immunoregulation of antibodies to human myelin basic protein, pharmaceutical compositions and method of treatment
CA2108963A1 (en) Compositions and Methods for Therapy and Prevention of Cancer, Aids and Anemia
DE69824619D1 (en) METHOD FOR PREVENTING KIDNEY POISONATION CAUSED BY CYCLOSPORINE OR TACROLIMUS
EP1304108A3 (en) Anti-arrhythmic composition and methods of treatment
EP0799618A3 (en) Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and teatment of cancer
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis
WO1990004977A3 (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
HK1015692A1 (en) Ctla-8 in combination with g-csf or with g-csf and il-6, and use of ctla-8, for treating infections
CA2201841A1 (en) Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
WO1999013894A3 (en) Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c
DK1019066T3 (en) Methods and Preparations for the Prevention and Treatment of Heartburn
Greenstein et al. A phase I clinical trial of human recombinant beta interferon in relapsing-remitting multiple sclerosis
CA2464947A1 (en) Combination therapy for treating disease
Arehart-Treichel The Retreat of Multiple Sclerosis
JPS63295516A (en) Use of human gamma-interferon for treating basal cell cancer
CA2080040A1 (en) Methods for preventing mycobacterial infections by administration of rifabutin
MX9801165A (en) Method and composition for treating asthma.
MY119359A (en) Use of consensus interferon for reducing the side effects of interferon treatment in viral hepatitis.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 145896

Country of ref document: SK

Ref document number: 2189990

Country of ref document: CA

Ref document number: PV1996-3295

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 285562

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1995918988

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995918988

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1996-3295

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1995918988

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1996-3295

Country of ref document: CZ